A comparative, randomized study of three different progesterone support of the luteal phase following IVF/ET program

The use of luteal phase support has been demonstrated in patients undergoing IVF/ET in cycles stimulated after pituitary desensitization with gonadotrophin releasing hormone agonists. However, it is still not clear which is the most suitable kind of supplementation. This study was designed to compare the absorption and the efficacy of three different luteal support. We randomly administered progesterone i.m. (50 mg/day), human chorionic gonadotrophin (hCG) (2000 IU every three days), progesterone vaginal cream (100 mg/day) or nothing (controls) to 176 women treated for assisted procreation. We were not able to show any statistical differences for the percentage of pregnancy rate between groups. The serum progestrerone (P) and 17-ß-estradiol (E2) and E2/P ratio levels of the luteal phase were compared with the control not supplemented group. All the treatments were able to increase significantly the luteal P values versus controls (p<0.01). Moreover, vaginal cream and natural P im significantly decreased E2/P ratio (p<0.05). Serum P levels were more steady with P vaginal cream than im injection. Vaginal cream for better bioavailability and acceptance appear the most suitable and comfortable method for luteal phase support. Similar content being viewed by others

Csapo A.I., Pulkkinen M.O., Ruttner B., Sauvage J.P., Wiest W.G. The significance of human corpus luteum in pregnancy maintenance. Am. J. Obstet. Gynecol. 112: 1061, 1972. Li T.C., Cooke L.D. Evaluation of luteal phase. Hum. Reprod. 6: 484, 1991. Jones G.S. The luteal phase defect. Fertil. Steril. 27: 351, 1975. Huang K.E., Muechler E.K., Schwartz F.K., Goggin M., Graham M. Serum progesterone levels in women treated with human menopausal gonadrotopin and human chorionic gonadotropin for in vitro fertilization. Fertil. Steril. 46: 903, 1986. Daya S. Efficacy of progesterone support in the luteal phase following in vitro fertilization and embryo transfer: metaanalysis of clinical trials. Hum. Reprod. 3: 731, 1988. Smitz J., Devroey P., Braekmans P., Camus M., Khan I., Staessen C., Van Waesberghe L., Wisanto A., Van Steirtenghem A.C. Management of failed cycles in IVF/GIFT program with the combination of a GnRH analogue and HMG Hum. Reprod. 2: 309, 1987. Smitz J., Devroey P., Camus M., Deshacht J., Khan I., Staessen C., Van Waesberghe L., Wisanto A., Van Steirteghem A.C. The luteal phase and early pregnancy after combined GnRH agonist/HMG tretment for superovulation in IVF or GIFT. Hum. Reprod. 3: 585, 1988. Kubik C.J. Luteal phase dysfunction following ovulation induction. Semin. Reprod. Endocrinol. 4: 293, 1986. Van Steirteghem A.C., Smitz J., Camus M., Van Waesberghe L., Deschacht J., Khan I., Staessen C., Wisanto A., Bourgain C., Devroey P. The luteal phase after in vitro fertilization and related procedures. Hum. Reprod. 3: 161, 1988. Macnamee M.C., Edwards R.G., Howies C.M. The influence of stimulation regimens and luteal phase support on the outcome of IVF. Hum. Reprod. 3: 43, 1988. Smith E.M., Anthony F.W., Gadd S.C., Masson G.M. Trial of support treatment with human chorionic gonadotrophin in the luteal phase after treatment with buserelin and human menopausal gonadotrophin in women taking part in an in vitro fertilisation programme. Br. Med. J. 298: 1483, 1989. Belaisch-Allart J., De Mouzon J., Lapouterle C., Mayer M. The effect of HCG supplementation after combined GnRH agonist/HMG treatment in an IVF programme. Hum. Reprod. 5: 163, 1990. Gidley—Baird A.A., O’Neill C., Sinosich M.J., Porter R.N., Pike I.L., Suanders D.M. Failure of implantation in human in vitro fertilization and embryo transfer patients: the effect of altered progesterone/estrogen ratios in human and mice. Fertil. Steril. 45: 69, 1986. Smitz J., Devroey P., Van Steirteghem A.C. Endocrinology in luteal phase and implantation. Br. Med. Bull. 46: 709, 1990. Lejeune B., Camus M., Deschact J., Leroy F. Differences in the luteal phases after failed or succesfull in vitro fertilization and embryo replacement. J. Vitro Fert Embryo Transfer. 3: 358, 1986. Buvat J., Marcolin G., Herbaut J.C., Dehaene J.L., Verbeck P., Fourlinnie J.C. A randomized trial of human chorionic gonadotropin support following in vitro fertilization and embryo transfer. Fertil. Steril. 49: 458, 1988. Latouche J., Crumeyrolles—Arias M., Jordan D., Kopp N., Augendre-Ferrante B., Cedard L., Haour F. GnRH receptors in human granulosa cells:anatomical localization and characterization by autoradiographic study. Endocrinology 125: 1739, 1989. Dehou M.F., Lejeune B., Arijs C., Leroy F. Endometrial morphology in stimulated in vitro fertilisation cycles and after steroid replacement therapy in cases of primary ovarian failure. Fertil. Steril. 48: 995, 1987. Brzyski R.G., Hofmann G.E., Scott R.T., Jones H.W. Effects of leuprolide acetate on follicular fluid hormone composition at oocyte retrieval for in vitro fertilization. Fertil. Steril. 54: 842, 1990. Yovich J.L., McColm S.C., Yovich J.M., Matson P.L. Early luteal serum progesterone concentrations are higher in pregnancy cycles. Fertil. Steril. 44: 185, 1985. Smitz J., Camus M., Devroey P., Erard P., Wisanto A., Van Steirteghem A.C. Incidence of severe ovarian hyperstimulation syndrome after GnRH agonist/hMG superovulation for in vitro fertilization. Hum. Reprod. 5: 933, 1990. Lindner C., Braendle W., Kohler S., Bettendorf G. Higher incidence of ovarian hyperstimulation syndrome after combined GnRH-Agonist-HMG therapy. Geburtshilfe Frauenheilkd. 49: 337, 1989. Herman A., Ron-El R., Golan A., Raziel A., Soffler Y., Caspi E. Pregnancy rate and ovarian hyperstimulation after luteal human chorionic gonadotrophin in in vitro fertilization stimulated with gonadotrophin-releasing hormone analog and menotropins. Fertil. Steril. 53: 92, 1990. Antoine J.M., Salat-Baroux J., Alvarez S., Cornet D., Tibi C., Mandelbaum J., Plachot M. Ovarian stimulation using human menopausal gonadotrophins with or without LHRH analogues in a long protocol for in vitro fertilization: a prospective randomized comparison. Hum. Reprod. 5: 565, 1990. Garcia J., Jones C., Acosta A., Wright G. Corpus luteum function after follicle aspiration for oocyte retrieval. Fertil. Steril. 36: 565, 1981. Halme J., Hammond M.G., Syrop C.H., Talbert L.M. Peritoneal macrophages modulate granulosa luteal cell progesterone production. J. Clin. Endocrinol. Metab. 61: 912, 1985. Kinel F.A., Ciaccio L.A. Suppression of immune response by progesterone. Endocrinol. Exp. 14: 27, 1980. Smitz J., Devroey P., Faguer P., Bourgain C., Camus M., Van Steirteghem A.C. A prospective randomized comparison of intramuscular or intravaginal natural progesterone as a luteal phase and early pregnancy supplement. Hum. Reprod. 7: 168, 1992. Enry R., Simoncini C., Chastelliere N., Lignieres B. Variations de la progesterone plasmatique induites par l’administration vaginale d’Utrogestan. J. Gynecol. Obstet. Biol. Reprod. 18: 229, 1989. Devroey P., Palermo G., Bourgain C., Van Waesberghe L., Smitz J. Progesterone administration in patients with absent ovaries. Int. J. Fertil. 34: 188, 1989. Bourgain C., Devroey P., Van Waesberghe L., Smitz J., Van Steirteghem A.C. Effects of natural progesterone on the morphology of the endometrium in patients with primary ovarian failure. Hum. Reprod. 5: 537, 1990. Author information Authors and Affiliations Rights and permissions About this article Cite this article Artini, P.G., Volpe, A., Angioni, S. et al. A comparative, randomized study of three different progesterone support of the luteal phase following IVF/ET program. J Endocrinol Invest 18, 51–56 (1995). https://doi.org/10.1007/BF03349699 Received: Accepted: Published: Issue date: DOI: https://doi.org/10.1007/BF03349699